 |
 |
 |
Journal articles
Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series
Abstract : The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease progression and decreases mortality. The most common adverse events of PFD are skin manifestations (25%), described as photosensitivity or rash, but they are not well characterized. The objective of the present real-life study was to address the question of skin manifestations in patients treated with PFD for IPF.
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01771415
Contributor : Laurent Jonchère <>
Submitted on : Thursday, April 26, 2018 - 1:43:16 PM
Last modification on : Thursday, January 14, 2021 - 11:16:08 AM
Long-term archiving on: : Tuesday, September 25, 2018 - 1:46:59 PM
Contributor : Laurent Jonchère <>
Submitted on : Thursday, April 26, 2018 - 1:43:16 PM
Last modification on : Thursday, January 14, 2021 - 11:16:08 AM
Long-term archiving on: : Tuesday, September 25, 2018 - 1:46:59 PM
File
Pirfenidone photosensitization...
Files produced by the author(s)